Evotec SEEVO +1.11%64 Altman Z-Score is 0.11 as of Jun. 27, 2026, which is 96% below its 10-year median of 3.06. GuruFocus rates EVO with a GF Score™ of 64/100 and a GF Value™ of $4.26 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 952 Drug Manufacturers companies, Evotec SE ranks worse than 85.4% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 0.12 is in distress zone. This implies bankruptcy possibility in the next two years.
Evotec SE has a Altman Z-Score of 0.11, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Evotec SE's Altman Z-Score or its related term are showing as below:
EVO'
s Altman Z-Score Range Over the Past 10 Years
Min: 0.05 Med: 3.06 Max: 10.83
Current: 0.12
During the past 13 years, Evotec SE's highest Altman Z-Score was 10.83. The lowest was 0.05. And the median was 3.06.
Evotec SE (NAS:EVO) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Evotec SE Altman Z-Score Related Terms
Evotec SE Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Evotec SE's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE Altman Z-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Evotec SE's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Evotec SE's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.1756
+
1.4
*
-0.5475
+
3.3
*
-0.1004
+
0.6
*
0.8954
+
1.0
*
0.4576
=
0.11
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Evotec SE (EVO) has a Altman Z-Score of 0.11 as of Jun. 27, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Evotec SE and its competitors. This is 96% below median its historical median of 3.06. Over the past decade, Evotec SE's Altman Z-Score has ranged from 0.05 to 10.83. According to the industry distribution chart, Evotec SE ranks #813 out of 952 companies in the Drug Manufacturers industry, placing it in the top 85.4%.
Is Evotec SE's Altman Z-Score too high?
Evotec SE's current Altman Z-Score of 0.11 is 96% below median its 10-year median of 3.06. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 10.83. The Drug Manufacturers industry median Altman Z-Score is 3.30. Evotec SE's value of 0.11 is 96.7% below this industry median. Based on the distribution chart, Evotec SE ranks #813 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Evotec SE has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Altman Z-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #813 out of 952 companies for Altman Z-Score. This places Evotec SE in the lower half of its industry. The industry median Altman Z-Score is 3.30. Evotec SE's value of 0.11 is 96.7% below this benchmark. Historically, Evotec SE's own Altman Z-Score has ranged from 0.05 to 10.83 over the past decade. While the company's 10-year median is 3.06 vs. the industry median of 3.30, Evotec SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Drug Manufacturers company?
The median Altman Z-Score among Drug Manufacturers companies is 3.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evotec SE's current Altman Z-Score of 0.11 is 96.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Evotec SE and its competitors. For the Drug Manufacturers industry, the median Altman Z-Score is 3.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current Altman Z-Score is 0.11, which is 96% below median its own 10-year median of 3.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (EVO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.26, compared to a current price of $2.74 — trading 35.7% below its estimated fair value. The current Altman Z-Score is 0.11, which is 96% below median its 10-year median of 3.06 and 96.7% below the Drug Manufacturers industry median of 3.30. Evotec SE's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Evotec SE (EVO), the current Altman Z-Score is 0.11 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (EVO) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of $2.74 is trading 35.7% below its estimated GF Value™ of $4.26.
GuruFocus considers Evotec SE to be Possible Value Trap.
Key valuation signals for EVO:
Altman Z-Score: 0.11 (96% below median its 10-year median of 3.06)
GF Value™: $4.26 vs. price of $2.74 (35.7% below fair value)
Industry Position: 96.7% below the Drug Manufacturers median (#813 of 952)
No single metric tells the full story. See the EVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
64GF Score
Get the complete analysis for EVO
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVO has been successfully added to your 
